Diplomat Pharmacy to Dispense Cotellic®

Diplomat Pharmacy, Inc. will dispense Cotellic^® (cobimetinib) in combination with the BRAF inhibitor Zelboraf^® (vemurafenib) to treat patients with advanced melanoma that is unrespectable or metastatic. The combination of Cotellic^® with Zelboraf^® helps patients with previously untreated BRAF V600 mutation-positive advanced melanoma live a median of one year (12.3 months) without their disease worsening, compared to 7.2 months with Zelboraf^® alone.

Cotellic^® is designed to selectively block the activity of MEK, one of a series of enzymes that make up a signaling pathway that helps regulate cell division and survival. Zelboraf^® binds to and inhibits mutant forms of BRAF, to interrupt abnormal signaling that can cause tumor growth.

"We are excited to dispense this combination treatment for patients suffering from advanced melanoma," said Gary Kadlec, president of Diplomat.

Zelboraf^® was the first prescription treatment for patients with unrespectable or metastatic melanoma with BRAF V600 mutation as detected by a validated test.